Skip to main content
Retour
Watch Compare

Immix Biopharma, Inc.

Qualité des données : 100%
IMMX
Nasdaq Manufacturing Chemicals
9,26 €
▼ 0,49 € (-5,03%)
Cap. Boursière: 511,30 M
Prix
9,65 €
Cap. Boursière
511,30 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -24,66 M
Capital efficient — spends only 3,66% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-455,78%
En dessous de la moyenne du secteur (-53,53%)
ROIC-318,61%
Net Margin-147,19%
Op. Margin-149,78%

Sécurité

Debt / Equity
N/A
Current Ratio1,53
Interest CoverageN/A

Valorisation

PE (TTM)
-17,37
En dessous de la moyenne du secteur (-1,48)
P/B Ratio61,86
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1366 pairs)
Métrique Action Médiane du Secteur
P/E -17,4 -1,5
P/B 61,9 1,6
ROE % -455,8 -53,5
Net Margin % -147,2 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

5 analystes
Strong Buy
Actuel
9,26 €
+89.6%
Objectif
17,56 €
14,80 €
15,00 €
23,00 €
Prévisions
P/E Prévisionnel -12,73
BPA Prévisionnel -0,73 €
CA Est. 56,42 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -0,73 €
-1,48 € – -0,07 €
 56,42 M 4
FY2026 -0,77 €
-0,96 € – -0,53 €
 0,0 5

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,16 € -0,28 € -75,0%
Q32025 -0,19 € -0,24 € -26,3%
Q22025 -0,16 € -0,22 € -37,5%
Q12025 -0,23 € -0,15 € +34,8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) 0,00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 20,00 M Net Income (TTM) -29,44 M
ROE -455,78% ROA -164,85%
Gross Margin N/A Operating Margin -149,78%
Net Margin -147,19% Free Cash Flow (TTM) -24,66 M
ROIC -318,61% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,53
Interest Coverage N/A Asset Turnover 1,12
Working Capital 5,73 M Tangible Book Value 8,26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -17,37 Forward P/E N/A
P/B Ratio 61,86 P/S Ratio 25,57
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -4,82%
Market Cap 511,30 M Enterprise Value 495,35 M
Per Share
EPS (Diluted TTM) -0,89 Revenue / Share 0,38
FCF / Share -0,47 OCF / Share -0,45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3,66% FCF Conversion 83,78%
SBC-Adj. FCF -27,27 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 20,00 M 20,00 M 20,00 M — —
Net Income -29,44 M -21,61 M -15,43 M -8,23 M -24,38 M
EPS (Diluted) -0,89 -0,76 -0,89 — —
Gross Profit — — — — —
Operating Income -29,96 M -22,67 M -16,14 M -8,22 M -1,35 M
EBITDA — — — — —
R&D Expenses 16,26 M 11,29 M 8,74 M 4,20 M 126 527,0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — 497,0 497,0 179 853,0
Income Tax 37 724,0 41 037,0 26 415,0 10 268,0 6 013,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 104,84 M 22,95 M 19,93 M 14,91 M 18,19 M
Total Liabilities 11,04 M 9,70 M 3,72 M 1,75 M 202 039,0
Shareholders' Equity 93,80 M 13,25 M 16,41 M 13,16 M 17,99 M
Total Debt — — — — —
Cash & Equivalents 93,93 M 17,68 M 17,51 M 13,44 M 17,64 M
Current Assets 101,24 M 20,20 M 19,79 M 14,90 M 18,19 M
Current Liabilities 10,11 M 8,69 M 3,72 M 1,27 M 202 039,0